Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 10/20 | 1.00 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.57 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.56 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29389224 | 1.00 | S1PR1 (1.00) | S1PR1S1PR5ALOX15HDAC4HDAC1 | |
| SCHEMBL13416529 | 0.90 | S1PR1 (1.00) | S1PR1S1PR5ALOX15HDAC4HDAC1 | |
| SCHEMBL29695849 | 0.90 | S1PR1 (0.82) | S1PR1S1PR5ALOX15HDAC4HDAC1 | |
| SCHEMBL24161900 | 0.87 | S1PR1 (0.80) | S1PR1S1PR5ALOX15HDAC4HDAC1 | |
| SCHEMBL15042804 | 0.87 | S1PR1 (0.78) | S1PR1S1PR5ALOX15HDAC4HDAC1 | |
| SCHEMBL1413283 | 0.85 | S1PR1 (0.88) | S1PR1S1PR5ALOX15HDAC4HDAC1 | |
| SCHEMBL13416916 | 0.83 | S1PR1 (0.77) | S1PR1S1PR5ALOX15HDAC4HDAC1 | |
| SCHEMBL13416846 | 0.83 | S1PR1 (0.76) | S1PR1S1PR5ALOX15HDAC4HDAC1 | |
| SCHEMBL14330169 | 0.82 | S1PR1 (0.75) | S1PR1S1PR5ALOX15HDAC4HDAC1 | |
| SCHEMBL2595803 | 0.82 | S1PR1 (0.68) | S1PR1S1PR5ALOX15HDAC6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566954-B2 | IMMUNOTHERAPY USING REDIRECTED ALLOGENEIC CELLS | YEDA RES & DEV (IL) | 2022-11-02 | — | — | EP | claimed |
| EP-2566954-B1 | IMMUNOTHERAPY USING REDIRECTED ALLOGENEIC CELLS | YEDA RES & DEV (IL) | 2018-08-29 | — | — | EP | claimed |
| WO-2018119080-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATIC DISORDERS | CORNELL UNIVERSITY (US) | 2018-06-28 | — | — | WO | claimed |
| US-9763980-B2 | Combined chemical modification of sphingosine-1-phosphate (S1P) and CXCR4 signalling pathways for hematopoietic stem cell (HSC) mobilization and engraftment | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-09-19 | — | — | US | claimed |
| US-20170216356-A1 | IMMUNOTHERAPY USING REDIRECTED ALLOGENEIC CELLS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-08-03 | — | — | US | claimed |
| US-9623049-B2 | Immunotherapy using redirected allogeneic cells | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-04-18 | — | — | US | claimed |
| US-20140193376-A1 | COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-07-10 | — | — | US | claimed |
| EP-2720690-A1 | COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT | Children's Medical Center Corporation (US) | 2014-04-23 | — | — | EP | claimed |
| US-20130156794-A1 | IMMUNOTHERAPY USING REDIRECTED ALLOGENEIC CELLS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2013-06-20 | — | — | US | claimed |
| EP-2566954-A1 | IMMUNOTHERAPY USING REDIRECTED ALLOGENEIC CELLS | Yeda Research and Development Co. Ltd. (IL) | 2013-03-13 | — | — | EP | claimed |
| WO-2012174522-A1 | COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-12-20 | — | — | WO | claimed |
| WO-2011140170-A1 | IMMUNOTHERAPY USING REDIRECTED ALLOGENEIC CELLS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2011-11-10 | — | — | WO | claimed |
| WO-2009074969-A2 | SPHINGOSINE-1-PHOSPHATE, ANALOGS AND ANTAGONISTS FOR USE AS MEDICAMENTS | UNIVERSITY OF LAUSANNE (CH) | 2009-06-18 | — | — | WO | claimed |
| WO-2023150572-A1 | METHODS FOR REDUCING ALCOHOL, DRUG, AND FOOD INTAKE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-4168034-A1 | RECOMBINANT POLYPEPTIDES AND COMBINATIONS FOR USE IN THE TREATMENT OF CANCER | Imunami Laboratories Pte. Ltd. (SG) | 2023-04-26 | — | — | EP | disclosed |
| US-20230084027-A1 | COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT | ENLIVEX THERAPEUTICS RDO LTD (IL) | 2023-03-16 | — | — | US | disclosed |
| US-20090029949-A1 | GPCR Ligands Identified by Computational Modeling | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-01-29 | — | — | US | disclosed |
| WO-2008124210-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING INFECTION USING LEUKOCYTE SEQUESTRATION AGENTS | EMORY UNIVERSITY (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140193376-A1 | COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT | S1PR1, S1PR4, S1PR3 | S1PR1 1/4885S1PR5 5/4885ALOX15 2523/4885 |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | S1PR1, EDNRA, S1PR3 | S1PR1 1/4885S1PR5 5/4885ALOX15 831/4885 |
| US-20130156794-A1 | IMMUNOTHERAPY USING REDIRECTED ALLOGENEIC CELLS | CD47, CD69, ICOS | S1PR1 150/4885S1PR5 161/4885ALOX15 1876/4885 |
| US-20090029949-A1 | GPCR Ligands Identified by Computational Modeling | LPAR3, LPAR2, LPAR1 | S1PR1 6/4885S1PR5 11/4885ALOX15 891/4885 |
| US-20170216356-A1 | IMMUNOTHERAPY USING REDIRECTED ALLOGENEIC CELLS | CD47, CD69, ICOS | S1PR1 150/4885S1PR5 161/4885ALOX15 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.